# Pulse Biosciences, Inc. (PLSE) · Edgar & Edgarette company card

> Pulse Biosciences (PLSE) reported revenue of $0 million in FY2025, operating margin -21983% against a 1.2% median for surgical & medical instruments & apparatus, equity 85.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1625101 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/PLSE) · [JSON](https://www.pops4.com/boards/company/PLSE.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $350,000 |
| Revenue growth, 1 year | — |
| Revenue growth per year | -29.5% |
| Operating margin | -21982.6% (prior year -Infinity%) |
| Net margin | -20794.6% |
| Operating cash flow | −$54M |
| Capital spending | $315,000 |
| Free cash flow | −$54M |
| Cash | $81M |
| Long-term debt | — |
| Total assets | $95M |
| Total equity | $81M |
| Equity ÷ assets | 85.3% |
| Return on equity | -90.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -10.11 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$54.1M in FY2025); operating loss: a margin of -21982.6% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $350K (FY2025). Experience: one year on record, down 29.5% a year over 4 years; operating margin -21982.6%, up from null. Soundness: equity 85.3% of assets, return on equity -90.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $204K and $366K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -21982.6% against a 1.2% median.

Range logged 2026-09-20, receipt 701e92e0f8995af5, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-04-09 ([filing](https://www.sec.gov/Archives/edgar/data/1625101/000143774926011831/0001437749-26-011831-index.htm))

## Recent filings

- 8-K · filed 2026-10-14 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1625101/000143774926032601/0001437749-26-032601-index.htm)
- 8-K · filed 2026-10-07 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1625101/000143774926032271/0001437749-26-032271-index.htm)
- 8-K · filed 2026-09-15 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1625101/000143774926030456/0001437749-26-030456-index.htm)
- 8-K · filed 2026-09-15 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1625101/000143774926030392/0001437749-26-030392-index.htm)
- 8-K · filed 2026-08-06 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1625101/000143774926026351/0001437749-26-026351-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1625101/000143774926026288/0001437749-26-026288-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001625101.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1625101

## Cite

POPS4, Edgar & Edgarette: Pulse Biosciences, Inc. (PLSE) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/PLSE. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.